AEON BIOPHARMA INC (AEON)

US00791X1000 - Common Stock

0.65  +0 (+0.08%)

Fundamental Rating

1

Taking everything into account, AEON scores 1 out of 10 in our fundamental rating. AEON was compared to 0 industry peers in the Unkown industry. AEON has a bad profitability rating. Also its financial health evaluation is rather negative. AEON has a expensive valuation and it also scores bad on growth.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

AEON had negative earnings in the past year.
AEON had a negative operating cash flow in the past year.
In multiple years AEON reported negative net income over the last 5 years.
AEON had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Industry RankSector Rank
ROA -116.07%
ROE N/A
ROIC N/A
ROA(3y)-176.64%
ROA(5y)-75.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AEON so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, AEON has more shares outstanding
There is no outstanding debt for AEON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

AEON has an Altman-Z score of -87.53. This is a bad value and indicates that AEON is not financially healthy and even has some risk of bankruptcy.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -87.53
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 0.48 indicates that AEON may have some problems paying its short term obligations.
AEON has a Quick Ratio of 0.48. This is a bad value and indicates that AEON is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.48
Quick Ratio 0.48

More info and screens

1

3. Growth

3.1 Past

AEON shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -409.61%.
EPS 1Y (TTM)-409.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

AEON is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.04% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y161.54%
EPS Next 2Y18.75%
EPS Next 3Y11.91%
EPS Next 5Y17.04%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

AEON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 0.89, the valuation of AEON can be described as very cheap.
When comparing the Price/Forward Earnings ratio of AEON to the average of the S&P500 Index (22.83), we can say AEON is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 0.89

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.87

4.3 Compensation for Growth

AEON's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.75%
EPS Next 3Y11.91%

More info and screens

0

5. Dividend

5.1 Amount

AEON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AEON BIOPHARMA INC

NYSEARCA:AEON (12/20/2024, 8:04:02 PM)

0.65

+0 (+0.08%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners35.66%
Inst Owner Change40.58%
Ins Owners39.39%
Ins Owner Change6.87%
Market Cap24.15M
Analysts82.86
Price Target5.1 (684.62%)
Short Float %0.77%
Short Ratio0.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)119.35%
Min EPS beat(2)-74.02%
Max EPS beat(2)312.73%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)146.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.89
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 0.87
EPS(TTM)-0.56
EYN/A
EPS(NY)0.73
Fwd EY112.98%
FCF(TTM)-1.29
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS0
BVpS-4.12
TBVpS-4.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -116.07%
ROE N/A
ROCE -349.13%
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-176.64%
ROA(5y)-75.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.48
Quick Ratio 0.48
Altman-Z -87.53
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-409.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y161.54%
EPS Next 2Y18.75%
EPS Next 3Y11.91%
EPS Next 5Y17.04%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y750.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-4773.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4773.09%
OCF growth 3YN/A
OCF growth 5YN/A